Table 2.
Treatment Efficacy Outcomes and Reasons for Nonresponse in Patients with G3-HCV
| Parameter | Group I (n=70) | Group II (n=87) | Group III (n=76) | p-value |
|---|---|---|---|---|
| HCV RNA undetectable at 24 weeks | 69 (98.6) | 87 (100) | 76 (100) | NS |
| SVR4 | 63 (90.0) | 85 (97.7) | 74 (97.4) | 0.04 |
| SVR12 | 61 (87.1) | 85 (97.7) | 74 (97.3) | 0.007 |
| No SVR12 | 9 (12.9) | 2 (2.2) | 2 (2.6) | 0.007 |
| Relapse | 8 (88.9) | 2 (2.2) | 2 (2.6) | - |
| No response | 1 (11.1) | 0 | 0 | - |
| Drop out | 0 | 1 (1.1) | 0 | - |
Data are presented as number (%). Group I, daclatasvir (DCV) + sofosbuvir (SOF) without ribavirin (RBV); group II, DCV/SOF with RBV flat dose of 800 mg/dL; group III, DCV/SOF with RBV weight-based dose.
G3-HCV, genotype 3 hepatitis C virus; NS, not significant; SVR, sustained viral response.